Miaomiao sheng

Dr. Miaomiao sheng


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 February 2023 in Functional & Integrative Genomics
Verified
Journal Article
Closed access
PDF file
MLMing Li
Ming Li
YZYuan Zhao
Yuan Zhao
HLHuimin Li
Huimin Li
XDXuming Deng
Xuming Deng
MSMiaomiao sheng
Miaomiao sheng

11 May 2024 in Cancer Cell International
Verified
Journal Article
Open access
PDF file
MLMing Li
Ming Li
SKShiyao Kang
Shiyao Kang
XDXuming Deng
Xuming Deng
HLHuimin Li
Huimin Li
YZYuan Zhao
Yuan Zhao
MSMiaomiao sheng
Miaomiao sheng
Triple-negative breast cancer (TNBC) is highly malignant and lacks effective biotherapeutic targets. The development of efficient anticancer drugs with low toxicity and few side effects is a hotspot in TNBC treatment research. Although erianin is known to have potent antitumor activity, its regulatory mechanism and target in TNBC have not been fully elucidated, hampering further drug development. This study showed that erianin can significantly inhibit TNBC cell proliferation and migration, promote cell apoptosis, and inhibit the growth of transplanted tumors in mice. Mechanistically, through network pharmacology analysis, molecular docking and cellular thermal shift assays, we preliminarily identified SRC as the cellular target of erianin. Erianin potently inhibited the expression of SRC, which mediated the anticancer effect of erianin in TNBC. Moreover, erianin can downregulate the expression of genes related to cholesterol synthesis and uptake by targeting SRC, interfering with cholesterol levels in TNBC, thereby inhibiting the progression of TNBC in vivo and in vitro. Taken together, our results suggest that erianin may inhibit the progression of TNBC by suppressing SRC-mediated cholesterol metabolism, and erianin has the great potential to be an effective treatment for TNBC patients.

23 March 2025 in Phytomedicine
Verified
Journal Article
Closed access
SKShiyao Kang
Shiyao Kang
HLHuimin Li
Huimin Li
MLMing Li
Ming Li
YZYuan Zhao
Yuan Zhao
JPJianyu Pang
Jianyu Pang
MSMiaomiao sheng
Miaomiao sheng

1 August 2020 in Pathology - Research and Practice
Verified
Journal Article
Closed access
FHFei Hu
Fei Hu
LCLi Chen
Li Chen
MBMing-Yu Bi
Ming-Yu Bi
LZLing Zheng
Ling Zheng
JHJi-Xiang He
Ji-Xiang He
MSMiaomiao sheng
Miaomiao sheng

Verified
Journal Article
Open access
PDF file
JPJianyu Pang
Jianyu Pang
HLHuimin Li
Huimin Li
XZXiaoling Zhang
Xiaoling Zhang
ZLZhengwei Luo
Zhengwei Luo
YCYongzhi Chen
Yongzhi Chen
MSMiaomiao sheng
Miaomiao sheng
Transcription factors (TFs) have been shown to play a key role in the occurrence and development of tumors, including triple-negative breast cancer (TNBC), with a worse prognosis. Machine learning is widely used for establishing prediction models and screening key tumor drivers. Current studies lack TF integration in TNBC, so targeted research on TF prognostic models and targeted drugs is beneficial to improve clinical translational application. The purpose of this study was to use the Least Absolute Shrinkage and Selection Operator to build a prognostic TFs model after cohort normalization based on housekeeping gene expression levels. Potential targeted drugs were then screened on the basis of molecular docking, and a multi-drug combination strategy was used for both in vivo and in vitro experimental studies. The machine learning model of TFs built by E2F8, FOXM1, and MYBL2 has broad applicability, with an AUC value of up to 0.877 at one year. As a high-risk clinical factor, its abnormal disorder may lead to upregulation of the activity of pathways related to cell proliferation. This model can also be used to predict the adverse effects of immunotherapy in patients with TNBC. Molecular docking was used to screen three drugs that target TFs: Trichostatin A (TSA), Doxorubicin (DOX), and Calcitriol. In vitro and in vivo experiments showed that TSA + DOX was able to effectively reduce DOX dosage, and TSA + DOX + Calcitriol may be able to effectively reduce the toxic side effects of DOX on the heart. In conclusion, the machine learning model based on three TFs provides new biomarkers for clinical and prognostic diagnosis of TNBC, and the combination targeted drug strategy offers a novel research perspective for TNBC treatment.

1 January 2021
Verified
Journal Article
Closed access
MBMingyu Bi
Mingyu Bi
LZLing Zheng
Ling Zheng
LCLi Chen
Li Chen
JHJixiang He
Jixiang He
CYChao Yuan
Chao Yuan
MSMiaomiao sheng
Miaomiao sheng